BRUSSELS (Reuters) - The European Commission proposed on Wednesday joint clinical assessments to determine whether approved new drugs and medical devices offer value for money and should be prescribed for patients within national healthcare systems.
The joint action, set to take more than three years to enter into force, would replace a largely national approach to health technology assessment (HTA) that duplicates work, limits transparency and impedes market access for innovation.
The Commission’s plans aim to make better use of available resources, to have a consistent methodology and to improve business predictability in a healthcare sector accounting for some 10 percent of the EU’s economic output.
Monique Goyens, director general of European consumer organization BEUC, welcomed the plans. She said too many new drugs or devices did not make a real difference compared to those already on the market, wasting taxpayers’ money.
“The Commission is right to encourage member states to work together so that only health technologies with an added value get the go-ahead,” she said in a statement.
HTA is used by most European countries.
Agencies such as Britain’s National Institute for Health and Care Excellence (NICE), France’s Haute Autorité de Santé (HAS) and Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) effectively act as gatekeepers to big markets.
Their role can be frustrating for drug companies that have already had their medicines cleared as safe and effective by the European Medicines Agency, but then need to submit different evidence to different agencies in different countries to get their products reimbursed.
This has led to growing calls for some degree of harmonization, although there has been voluntary cooperation for years, with an EU-wide network set up in 2013.
The Commission is proposing joint work on clinical assessments, scientific consultations with business, identification of emerging health technologies and voluntary cooperation on, for example, surgical procedures.
A group of representatives from national authorities would be responsible for overseeing joint work.
National HTA authorities will still be responsible for determining pricing and reimbursement, albeit using the joint assessments.
The rules will apply some three years after approval by the European Parliament and EU members. There will then be a further three-year transition period for EU countries to adapt.
The Commission said it envisaged 10-15 assessments could start in the first year, rising to 65 towards the end of the transition period.
The changes will therefore happen after Britain has exited the European Union and will have to be factored into the next EU budget covering the period after 2020.
Reporting by Philip Blenkinsop with; additional reporting by Samantha Koester; editing by Robert-Jan Bartunek/Mark Heinrich